UPTAKE OF NEWER SECOND-LINE DIABETES MEDICATIONS IN REAL-WORLD VULNERABLE POPULATIONS

被引：0
|
作者：
Ogunsanmi, D. [1 ]
Harrison, A. T. [2 ]
Kovesdy, C. P. [1 ]
Surbhi, S. [1 ]
机构：
[1] Univ Tennessee, Hlth Sci Ctr, Memphis, TN 38163 USA
[2] Rhodes Coll, Memphis, TN 38112 USA
来源：
VALUE IN HEALTH | 2022年 / 25卷 / 07期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
HSD112
引用
收藏
页码：S499 / S499
页数：1
相关论文
共 50 条
  • [41] Ramucirumab as Second-Line Therapy in Metastatic Gastric Cancer: Real-World Data from the RAMoss Study
    Di Bartolomeo, Maria
    Niger, Monica
    Tirino, Giuseppe
    Petrillo, Angelica
    Berenato, Rosa
    Laterza, Maria Maddalena
    Pietrantonio, Filippo
    Morano, Federica
    Antista, Maria
    Lonardi, Sara
    Fornaro, Lorenzo
    Tamberi, Stefano
    Giommoni, Elisa
    Zaniboni, Alberto
    Rimassa, Lorenza
    Tomasello, Gianluca
    Sava, Teodoro
    Spada, Massimiliano
    Latiano, Tiziana
    Bittoni, Alessandro
    Bertolini, Alessandro
    Proserpio, Ilaria
    Bencardino, Katia Bruna
    Graziano, Francesco
    Beretta, Giordano
    Galdy, Salvatore
    Ventriglia, Jole
    Scagnoli, Simone
    Spallanzani, Andrea
    Longarini, Raffaella
    De Vita, Ferdinando
    TARGETED ONCOLOGY, 2018, 13 (02) : 227 - 234
  • [42] Real-World Effectiveness of Second-Line Therapies for Metastatic Non-Small Cell Lung Cancer
    Bazhenova, L.
    Cai, B.
    Gentile, D.
    Kari, G.
    Feinberg, B.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (03) : E22 - E22
  • [43] A real-world effectiveness of second-line osimertinib in NSCLC patients: A multi-institutions study in Taiwan
    Chen, Hui-Yu
    Chang, Kaicheng
    Shao, Shih-Chieh
    Fang, Yueh-Fu
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2022, 31 : 343 - 343
  • [44] Early initiation of second-line therapy in primary immune thrombocytopenia: insights from real-world evidence
    Adam Cuker
    Brian Buckley
    Marie-Catherine Mousseau
    Aditya Anand Barve
    Jens Haenig
    James B. Bussel
    Annals of Hematology, 2023, 102 : 2051 - 2058
  • [45] Real-world experience of second-line axitinib in metastatic renal cell carcinoma: analysis of the Swedish population
    Jakobsson, Maria
    Strambi, Angela
    Nilsson, Fredrik
    Arpegard, Johannes
    Dalen, Johan
    FUTURE ONCOLOGY, 2024, 20 (20) : 1385 - 1392
  • [46] Second-Line Chemotherapy in Elderly Patients with Advanced Biliary Tract Cancer: A Multicenter Real-World Study
    Rizzo, Alessandro
    Salati, Massimiliano
    Frega, Giorgio
    Merz, Valeria
    Caputo, Francesco
    Di Federico, Alessandro
    Palloni, Andrea
    Carloni, Riccardo
    Ricci, Angela Dalia
    Gadaleta-Caldarola, Gennaro
    Messina, Carlo
    Spallanzani, Andrea
    Gelsomino, Fabio
    Benatti, Stefania
    Luppi, Gabriele
    Melisi, Davide
    Dominici, Massimo
    Brandi, Giovanni
    MEDICINA-LITHUANIA, 2022, 58 (11):
  • [47] Immune checkpoint inhibitor retreatment in second-line treatment of esophageal cancer: A real-world study.
    Kang, Yixin
    Zhang, Dianbao
    Mi, Youjia
    Niu, Xiedong
    Kang, Yuan
    Xie, Dongjie
    Li, Wenyao
    Zhang, Ce
    Yang, Junqiang
    Yao, Jun
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [48] EFfectiveness and Safety Profile of Lurbinectedin in Second-Line Small Cell Lung Cancer: A Real-World Study
    Ganti, A. K.
    Allan, V.
    Merola, D.
    Estrin, A.
    Boccuti, A.
    Rengarajan, B.
    Baratta, C.
    Prince, P.
    Li, W.
    Cao, Y.
    D'Agostino, R. B., Jr.
    Poole, E. M.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S378 - S379
  • [49] Risk of pancreatic diseases by second-line anti diabetes drug class: real world based evidence
    Paul, S.
    Green, J. B.
    Atherton, J.
    Montvida, O.
    DIABETOLOGIA, 2017, 60 : S69 - S70
  • [50] Real-World Outcomes of Stage IV NSCLC with PD-L1 ≥ 50% Treated with First-Line Pembrolizumab: Uptake of Second-Line Systemic Therapy
    Rittberg, Rebekah
    Leung, Bonnie
    Shokoohi, Aria
    Pender, Alexandra
    Wong, Selina
    Al-Hashami, Zamzam
    Wang, Ying
    Ho, Cheryl
    CURRENT ONCOLOGY, 2023, 30 (06) : 5299 - 5308
12345